DUBLIN, Oct. 20, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hqlltm/2016_emerging) has announced the addition of the "2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market" report to their offering.
This new report contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:
- Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years
- Mortality statistics and scientific views on the etiology of major types of cancer
- Test volume and sales forecasts for 40 tumor markers performed in US hospitals
- Current instrumentation technologies and feature comparison of leading analyzers
- Sales and market shares of leading suppliers
- Emerging diagnostic technologies and their potential market applications
- Product development opportunities
- Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies
- Business opportunities and strategic recommendations for suppliers
Companies Mentioned
- Abbott- Affymetrix- Beckman Coulter/Danaher- Becton Dickinson- bioMerieux- Bio-Rad- Cepheid- Diamedix- DiaSorin- Eiken Chemical- Elitech Group- Enzo Biochem- Fujirebio- Grifols- Hologic/Gen-Probe- ID Biomedical/GSK- Kreatech/Leica- Lonza- Ortho-Clinical Diagnostics- Qiagen- Roche- Scienion- Sequenom- SeraCare- Siemens- Takara Bio- Thermo Fisher/Life Technology- Wallac/PE- Wako
For more information visit http://www.researchandmarkets.com/research/hqlltm/2016_emerging
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
